乐普医疗(300003) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥1,922,028,839.15, a decrease of 21.14% compared to the same period last year[4] - Net profit attributable to shareholders was ¥481,871,134.58, down 19.27% year-on-year[4] - The revenue from the medical device segment was ¥885,619,800, a year-on-year decrease of 18.69%[8] - The cardiovascular intervention business generated revenue of ¥438,018,100, a year-on-year increase of 5.80%[8] - The pharmaceutical segment's revenue was ¥792,915,700, down 15.69% year-on-year[9] - Total operating revenue for the current period is ¥1,922,028,839.15, a decrease of 21.1% from ¥2,437,202,386.92 in the previous period[23] - Net profit for the current period is ¥492,760,543.46, a decline of 20.3% compared to ¥618,318,467.79 in the previous period[25] - Basic earnings per share for the current period is ¥0.2594, down from ¥0.3205 in the previous period[25] - Total comprehensive income for the current period is ¥483,962,303.22, a decrease from ¥657,211,412.12 in the previous period[25] Cash Flow and Assets - The net cash flow from operating activities was ¥141,518,257.63, an increase of 205.45% compared to the previous year[4] - Cash flow from operating activities for the current period is ¥141,518,257.63, compared to a negative cash flow of -¥134,203,435.01 in the previous period[26] - Cash received from sales of goods and services is ¥1,636,352,953.22, down from ¥2,221,855,789.57 in the previous period[26] - The company's total assets at the end of the reporting period were ¥25,508,525,579.77, an increase of 1.94% from the end of the previous year[4] - The company's total liabilities were CNY 7.50 billion, slightly down from CNY 7.52 billion at the beginning of the period[22] - The company’s total equity reached CNY 18.01 billion, up from CNY 17.50 billion at the beginning of the period[22] - The cash and cash equivalents decreased to CNY 4.13 billion from CNY 4.22 billion at the beginning of the period[20] - The company’s inventory decreased to CNY 2.22 billion from CNY 2.29 billion at the beginning of the period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 91,316[12] - The largest shareholder, China Shipbuilding Industry Group Company, holds 12.98% of shares, totaling 244,063,788 shares[12] - The second-largest shareholder, Pu Zhongjie, holds 12.13% of shares, totaling 228,074,749 shares, with 171,056,062 shares under lock-up[12] - WP Medical Technologies, Inc. holds 6.59% of shares, totaling 123,968,600 shares, with 92,976,450 shares under lock-up[12] - The top ten shareholders account for a significant portion of the company's equity, with the largest ten shareholders holding a combined total of 63.88%[12] - The report indicates that there are no changes in the number of restricted shares for major shareholders during the reporting period[16] - The total number of restricted shares held by Pu Zhongjie remains at 171,056,062 shares, with no shares released during the period[16] Research and Development - The company has not disclosed any new product developments or technological advancements in this report[17] - The company received NMPA approval for its self-developed coronary intravascular shockwave catheter, obtaining Class III medical device registration with certificate number 20243010074[18] - The company also obtained NMPA approval for its self-developed coronary papillary balloon dilation catheter, with registration certificate number 20243030105[18] - The company's subsidiary, Lepu Pharmaceutical Technology Co., Ltd., received NMPA approval for its self-developed Oseltamivir phosphate dry suspension, with drug approval number H20243080[18] - The company’s subsidiaries participated in the centralized procurement bidding for Amoxicillin and other drugs, with plans to win bids for Clopidogrel hydrogen sulfate tablets, Atorvastatin calcium tablets, and Rosuvastatin calcium tablets[19] - The company’s subsidiary, Shanghai Minwei Biotechnology Co., Ltd., is conducting two Phase II clinical trials for the self-developed GLP-1/GCGR/GIP-Fc fusion protein MWN101 for the treatment of type 2 diabetes and obesity, with the first subject dosed successfully[19] Investment Activities - The company reported a net investment loss of ¥4,292,600, a decrease of 80.07% compared to the previous year[9] - Investment income for the current period shows a loss of ¥4,292,647.74, an improvement from a loss of ¥21,542,984.71 in the previous period[23] - Total cash inflow from investment activities was approximately CNY 210.29 million, a decrease from CNY 289.84 million in the previous period[27] - Cash outflow from investment activities totaled CNY 490.31 million, slightly down from CNY 502.25 million year-over-year[27] - Net cash flow from investment activities was negative CNY 280.02 million, compared to negative CNY 212.41 million in the prior year[27] Financing Activities - Cash inflow from financing activities amounted to CNY 646.68 million, a slight decrease from CNY 656.42 million[27] - Net cash flow from financing activities was negative CNY 52.06 million, contrasting with a positive CNY 250.48 million in the same period last year[27] - The net increase in cash and cash equivalents was negative CNY 188.90 million, compared to negative CNY 138.75 million previously[27] - The ending balance of cash and cash equivalents was CNY 3.91 billion, down from CNY 5.17 billion year-over-year[27] - The company reported a significant increase in cash paid for fixed assets, intangible assets, and other long-term assets, totaling CNY 144.13 million, compared to CNY 210.65 million in the previous period[27] - Cash received from borrowings was CNY 634.09 million, slightly up from CNY 617.00 million[27] Audit and Reporting - The company’s first quarter report was not audited[27] - There is no mention of market expansion or mergers and acquisitions in the current report[17] - The report does not provide specific future outlook or performance guidance for the upcoming quarters[17]